Strides Pharma Science gets USFDA EIR for Puducherry facility

Bengaluru: Strides Pharma Science Limited has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Puducherry manufacturing facility, stating the inspection conducted between February 20-24, 2023 has been closed.

The USFDA has classified the facility from Official Action Indicated (OAI) to Voluntary Action Indicated (VAI).

The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.

Strides Puducherry facility caters to the U.S., other regulated markets, and institutional businesses and produces finished dosage formulation products across multiple dosage formats.

Read also: Strides, Orbicular ink pact to develop range of nasal sprays

"Consequent to this reclassification by the USFDA, the filed ANDAs from this facility will now start receiving approvals. The Company remains committed to the highest standards of compliance and will continue to focus on manufacturing high-quality pharmaceutical products for the Global markets," the company stated in a BSE filing.

Medical Dialogues team had earlier reported that the company had successfully completed the inspection carried out by the World Health Organization (WHO) at its Puducherry facility.

Read also: Strides Pharma Science successfully concludes WHO inspection at Puducherry facility